Haymarket names Barsamian med-ed unit head

Share this article:
Dik Barsamian joined Haymarket as executive VP in charge of Haymarket Medical Education LP. Haymarket, a non-accredited provider, partners with medical schools to deliver educational programming and publications. Before coming to Haymarket, Barsamian was head of Thomson Medical Education, the division of Thomson Healthcare which was sold in April to private equity firm ABRY Partners for an undisclosed sum and renamed KnowledgePoint360. He replaces David Helgans, who left Haymarket to become president of CME Scholar, part of Grey Healthcare Group’s International Meetings & Science. Barsamian said he will look to build on his new company’s therapeutic expertise in a number of areas, including pediatric and women’s health education, as well as its ability to deliver education in innovative ways. “One of Haymarket’s strengths is its diverse in-house expertise and ability to leverage varied communications channels, including Web, handheld and print delivery vehicles,” he told MM&M. “These capabilities are very important to meet the educational needs of healthcare professionals in what is a dynamic and evolving medical education arena.” (Haymarket Medical Education and Haymarket Business Media, publisher of MM&M, are both divisions of Haymarket Media Group.) A longtime manager with extensive sales and marketing experience, Barsamian spent 15 years at Thomson. His senior management roles there included manager of the PDR sales and marketing operation. Most recently he was general manager of Physicians World, Gardiner-Caldwell, Scientific Connexions and Professional Postgraduate Services, Thomson’s promotional education, publications planning and accredited education businesses. In his new role, he will work out of Haymarket Medical’s Montvale, NJ, office and report to Lee Maniscalco, CEO of Haymarket Medical. “Dik’s strong knowledge of drug information and CME will prove to be invaluable, as it aligns perfectly with our core medical businesses of Monthly Prescribing Reference and the Montvale group,” said Maniscalco. Prior to his career at Thomson, Barsamian spent four years as an AstraZeneca sales rep.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...